Akèy › Skleroz Miltip › Maryland
Etid klinik pou Skleroz Miltip nan Maryland
17 etid pou Skleroz Miltip ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Baltimore
- TG Therapeutics Investigational Trial Site, Glen Burnie
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06433752Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Month – 99 Years · Tout sèks · Mizajou Sep 22, 2026 · NCT00794352Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Sep 16, 2026 · NCT02784210Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou Sep 16, 2026 · NCT00001248RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Sunstone Therapies, PC, Rockville
- Sheppard Pratt, Towson
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Baltimore Veterans Affairs Medical Center- Site Number : 8400163, Baltimore
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 15, 2026 · NCT07325292Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 120 · Tout sèks · Mizajou Aug 31, 2026 · NCT01730131Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 27, 2026 · NCT03109288A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Mid Atlantic Epilepsy and Sleep Ctr, Bethesda
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT07225504Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
- Johns Hopkins University, Baltimore
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Jul 17, 2026 · NCT07497399Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
- Johns Hopkins University, Baltimore
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Jun 9, 2026 · NCT06170970Pathological Basis of MRI Signal Changes in Multiple Sclerosis
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou Jun 5, 2026 · NCT02659956Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Jun 5, 2026 · NCT05849467Genes and Environment in Multiple Sclerosis
- National Institute of Neurological Disorders and Stroke, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou May 14, 2026 · NCT01353547Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
- Johns Hopkins University, Baltimore
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou May 6, 2026 · NCT07389590A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Evidera INC., Bethesda
- Evidera, Bethesda
Ap rekriteEtid obsèvasyon
Tout laj · Fanm · Mizajou Nov 20, 2025 · NCT05170126Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.